PHARMING GRP EO-,01/ NL0010391025 /
11/11/2024 8:07:22 | Diferencia -0.0195 | Volumen | Bid14:55:24 | Ask14:55:46 | Máximo del día | Price Change Band |
---|---|---|---|---|---|---|
0.7305EUR | -2.60% | 0 Volumen de negocios: 0.0000 |
0.7395Volumen de oferta: 2,760 | 0.7450Tamaño/ Volumen/ Formato de Ask: 2,760 | 0.7305 | 0.7305 |
GlobeNewswire
01/08
Pharming Group reports second quarter and first half 2024 financial results and provides business up...
GlobeNewswire
18/07
Pharming Group to report second quarter and first half 2024 financial results on August 1
GlobeNewswire
21/05
Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
GlobeNewswire
08/05
Pharming Group reports first quarter 2024 financial results and provides business update
GlobeNewswire
24/04
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 20...
GlobeNewswire
08/04
Pharming announces completion of enrollment in pediatric clinical trial of leniolisib
GlobeNewswire
29/02
Pharming Group to report fourth quarter and full year 2023 financial results on March 14
GlobeNewswire
08/01
Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update
GlobeNewswire
13/12/2023
Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies ...
GlobeNewswire
21/11/2023
Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years fo...
GlobeNewswire
12/10/2023
Pharming Group to report third quarter 2023 financial results on October 26
GlobeNewswire
25/09/2023
Pharming Group reports on results of the 2023 Extraordinary General Meeting of Shareholders
GlobeNewswire
08/11/2013
PHARMING AND SANTARUS ANNOUNCE NEW DATA FROM OPEN-LABEL REPEAT TREATMENT STUDY WITH RUCONEST
GlobeNewswire
09/10/2013
Pharming announces €12.0 million private equity placement with institutional investors
- Primera página
- Atrás
- 1
- 2
- Siguiente
- Última página